Volitionrx Ltd (VNRX) Stock Competitors & Peer Comparison
See (VNRX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VNRX | $1.28 | -0.78% | 7.6M | -0.61 | -$2.12 | N/A |
| VRTX | $491.34 | +2.32% | 124.7B | 26.11 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $632.90 | +2.06% | 65.2B | 13.87 | $45.63 | +0.58% |
| ARGX | $887.18 | -0.17% | 54.9B | 80.07 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $8.85 | +5.73% | 39.7B | -2.13 | -$4.15 | N/A |
| ALNY | $291.37 | -0.61% | 38.9B | 52.55 | $5.55 | N/A |
| RVMD | $182.08 | +2.19% | 38.7B | -25.75 | -$7.07 | N/A |
| ONC | $279.89 | +1.65% | 29.9B | 62.62 | $4.47 | N/A |
Stock Comparison
VNRX vs VRTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, VRTX has a market cap of 124.7B. Regarding current trading prices, VNRX is priced at $1.28, while VRTX trades at $491.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas VRTX's P/E ratio is 26.11. In terms of profitability, VNRX's ROE is +0.74%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, VNRX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check VRTX's competition here
VNRX vs VRNA Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VNRX is priced at $1.28, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VNRX's ROE is +0.74%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, VNRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check VRNA's competition here
VNRX vs REGN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, REGN has a market cap of 65.2B. Regarding current trading prices, VNRX is priced at $1.28, while REGN trades at $632.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas REGN's P/E ratio is 13.87. In terms of profitability, VNRX's ROE is +0.74%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VNRX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check REGN's competition here
VNRX vs ARGX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ARGX has a market cap of 54.9B. Regarding current trading prices, VNRX is priced at $1.28, while ARGX trades at $887.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ARGX's P/E ratio is 80.07. In terms of profitability, VNRX's ROE is +0.74%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, VNRX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ARGX's competition here
VNRX vs SGEN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VNRX is priced at $1.28, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VNRX's ROE is +0.74%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VNRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check SGEN's competition here
VNRX vs RVMDW Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RVMDW has a market cap of 39.7B. Regarding current trading prices, VNRX is priced at $1.28, while RVMDW trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RVMDW's P/E ratio is -2.13. In terms of profitability, VNRX's ROE is +0.74%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, VNRX is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check RVMDW's competition here
VNRX vs ALNY Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ALNY has a market cap of 38.9B. Regarding current trading prices, VNRX is priced at $1.28, while ALNY trades at $291.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ALNY's P/E ratio is 52.55. In terms of profitability, VNRX's ROE is +0.74%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, VNRX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ALNY's competition here
VNRX vs RVMD Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RVMD has a market cap of 38.7B. Regarding current trading prices, VNRX is priced at $1.28, while RVMD trades at $182.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RVMD's P/E ratio is -25.75. In terms of profitability, VNRX's ROE is +0.74%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, VNRX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RVMD's competition here
VNRX vs ONC Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ONC has a market cap of 29.9B. Regarding current trading prices, VNRX is priced at $1.28, while ONC trades at $279.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ONC's P/E ratio is 62.62. In terms of profitability, VNRX's ROE is +0.74%, compared to ONC's ROE of +0.12%. Regarding short-term risk, VNRX is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ONC's competition here
VNRX vs MRNA Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MRNA has a market cap of 26.7B. Regarding current trading prices, VNRX is priced at $1.28, while MRNA trades at $67.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MRNA's P/E ratio is -8.25. In terms of profitability, VNRX's ROE is +0.74%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, VNRX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check MRNA's competition here
VNRX vs ROIV Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, VNRX is priced at $1.28, while ROIV trades at $34.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ROIV's P/E ratio is -37.81. In terms of profitability, VNRX's ROE is +0.74%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, VNRX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ROIV's competition here
VNRX vs BNTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, VNRX is priced at $1.28, while BNTX trades at $91.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BNTX's P/E ratio is -19.74. In terms of profitability, VNRX's ROE is +0.74%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, VNRX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BNTX's competition here
VNRX vs UTHR Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, UTHR has a market cap of 23B. Regarding current trading prices, VNRX is priced at $1.28, while UTHR trades at $542.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas UTHR's P/E ratio is 20.03. In terms of profitability, VNRX's ROE is +0.74%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VNRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check UTHR's competition here
VNRX vs INCY Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, INCY has a market cap of 22.7B. Regarding current trading prices, VNRX is priced at $1.28, while INCY trades at $113.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas INCY's P/E ratio is 15.29. In terms of profitability, VNRX's ROE is +0.74%, compared to INCY's ROE of +0.29%. Regarding short-term risk, VNRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check INCY's competition here
VNRX vs INSM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, INSM has a market cap of 22.4B. Regarding current trading prices, VNRX is priced at $1.28, while INSM trades at $103.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas INSM's P/E ratio is -17.98. In terms of profitability, VNRX's ROE is +0.74%, compared to INSM's ROE of -1.30%. Regarding short-term risk, VNRX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check INSM's competition here
VNRX vs BGNE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VNRX is priced at $1.28, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VNRX's ROE is +0.74%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, VNRX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BGNE's competition here
VNRX vs DNA-WT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VNRX is priced at $1.28, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VNRX's ROE is +0.74%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, VNRX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check DNA-WT's competition here
VNRX vs NBIX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, VNRX is priced at $1.28, while NBIX trades at $168.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas NBIX's P/E ratio is 24.35. In terms of profitability, VNRX's ROE is +0.74%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, VNRX is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check NBIX's competition here
VNRX vs ASND Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ASND has a market cap of 16.2B. Regarding current trading prices, VNRX is priced at $1.28, while ASND trades at $260.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ASND's P/E ratio is -107.75. In terms of profitability, VNRX's ROE is +0.74%, compared to ASND's ROE of -56.42%. Regarding short-term risk, VNRX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ASND's competition here
VNRX vs GMAB Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, GMAB has a market cap of 16B. Regarding current trading prices, VNRX is priced at $1.28, while GMAB trades at $26.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas GMAB's P/E ratio is 18.79. In terms of profitability, VNRX's ROE is +0.74%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, VNRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check GMAB's competition here
VNRX vs JAZZ Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, JAZZ has a market cap of 14.4B. Regarding current trading prices, VNRX is priced at $1.28, while JAZZ trades at $230.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas JAZZ's P/E ratio is 17.89. In terms of profitability, VNRX's ROE is +0.74%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, VNRX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check JAZZ's competition here
VNRX vs EXEL Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, EXEL has a market cap of 13.8B. Regarding current trading prices, VNRX is priced at $1.28, while EXEL trades at $54.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas EXEL's P/E ratio is 16.40. In terms of profitability, VNRX's ROE is +0.74%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, VNRX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check EXEL's competition here
VNRX vs BBIO Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BBIO has a market cap of 13.8B. Regarding current trading prices, VNRX is priced at $1.28, while BBIO trades at $70.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BBIO's P/E ratio is -18.78. In terms of profitability, VNRX's ROE is +0.74%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, VNRX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BBIO's competition here
VNRX vs IONS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, IONS has a market cap of 13.4B. Regarding current trading prices, VNRX is priced at $1.28, while IONS trades at $81.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas IONS's P/E ratio is -47.20. In terms of profitability, VNRX's ROE is +0.74%, compared to IONS's ROE of -0.59%. Regarding short-term risk, VNRX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check IONS's competition here
VNRX vs KRTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VNRX is priced at $1.28, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VNRX's ROE is +0.74%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VNRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check KRTX's competition here
VNRX vs AXSM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, AXSM has a market cap of 12.4B. Regarding current trading prices, VNRX is priced at $1.28, while AXSM trades at $241.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas AXSM's P/E ratio is -63.10. In terms of profitability, VNRX's ROE is +0.74%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, VNRX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check AXSM's competition here
VNRX vs MDGL Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MDGL has a market cap of 11.8B. Regarding current trading prices, VNRX is priced at $1.28, while MDGL trades at $512.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MDGL's P/E ratio is -40.05. In terms of profitability, VNRX's ROE is +0.74%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, VNRX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check MDGL's competition here
VNRX vs BMRN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BMRN has a market cap of 11.4B. Regarding current trading prices, VNRX is priced at $1.28, while BMRN trades at $59.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BMRN's P/E ratio is 28.37. In terms of profitability, VNRX's ROE is +0.74%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, VNRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BMRN's competition here
VNRX vs RNAM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VNRX is priced at $1.28, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VNRX's ROE is +0.74%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VNRX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RNAM's competition here
VNRX vs TECH Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, VNRX is priced at $1.28, while TECH trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TECH's P/E ratio is 154.58. In terms of profitability, VNRX's ROE is +0.74%, compared to TECH's ROE of +0.05%. Regarding short-term risk, VNRX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check TECH's competition here
VNRX vs ARWR Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ARWR has a market cap of 11.1B. Regarding current trading prices, VNRX is priced at $1.28, while ARWR trades at $78.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ARWR's P/E ratio is -36.69. In terms of profitability, VNRX's ROE is +0.74%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, VNRX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check ARWR's competition here
VNRX vs KRYS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, KRYS has a market cap of 11B. Regarding current trading prices, VNRX is priced at $1.28, while KRYS trades at $372.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas KRYS's P/E ratio is 49.77. In terms of profitability, VNRX's ROE is +0.74%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VNRX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check KRYS's competition here
VNRX vs SMMT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, SMMT has a market cap of 10.9B. Regarding current trading prices, VNRX is priced at $1.28, while SMMT trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas SMMT's P/E ratio is -8.76. In terms of profitability, VNRX's ROE is +0.74%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, VNRX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check SMMT's competition here
VNRX vs CYTK Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CYTK has a market cap of 10.2B. Regarding current trading prices, VNRX is priced at $1.28, while CYTK trades at $82.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CYTK's P/E ratio is -14.10. In terms of profitability, VNRX's ROE is +0.74%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, VNRX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check CYTK's competition here
VNRX vs RXDX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VNRX is priced at $1.28, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VNRX's ROE is +0.74%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VNRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RXDX's competition here
VNRX vs CORT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CORT has a market cap of 9.4B. Regarding current trading prices, VNRX is priced at $1.28, while CORT trades at $87.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CORT's P/E ratio is 249.49. In terms of profitability, VNRX's ROE is +0.74%, compared to CORT's ROE of +0.08%. Regarding short-term risk, VNRX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check CORT's competition here
VNRX vs ALKS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ALKS has a market cap of 9.2B. Regarding current trading prices, VNRX is priced at $1.28, while ALKS trades at $55.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ALKS's P/E ratio is 57.98. In terms of profitability, VNRX's ROE is +0.74%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, VNRX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ALKS's competition here
VNRX vs IBRX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, VNRX is priced at $1.28, while IBRX trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas IBRX's P/E ratio is -27.22. In terms of profitability, VNRX's ROE is +0.74%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, VNRX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check IBRX's competition here
VNRX vs NUVL Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VNRX is priced at $1.28, while NUVL trades at $123.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas NUVL's P/E ratio is -21.71. In terms of profitability, VNRX's ROE is +0.74%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VNRX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check NUVL's competition here
VNRX vs KYMR Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, KYMR has a market cap of 8.9B. Regarding current trading prices, VNRX is priced at $1.28, while KYMR trades at $108.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas KYMR's P/E ratio is -30.63. In terms of profitability, VNRX's ROE is +0.74%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, VNRX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check KYMR's competition here
VNRX vs HALO Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, HALO has a market cap of 8.9B. Regarding current trading prices, VNRX is priced at $1.28, while HALO trades at $74.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas HALO's P/E ratio is 16.23. In terms of profitability, VNRX's ROE is +0.74%, compared to HALO's ROE of +1.26%. Regarding short-term risk, VNRX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check HALO's competition here
VNRX vs IMGN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VNRX is priced at $1.28, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VNRX's ROE is +0.74%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VNRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check IMGN's competition here
VNRX vs TGTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, VNRX is priced at $1.28, while TGTX trades at $55.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TGTX's P/E ratio is 19.19. In terms of profitability, VNRX's ROE is +0.74%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, VNRX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check TGTX's competition here
VNRX vs BPMC Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VNRX is priced at $1.28, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VNRX's ROE is +0.74%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, VNRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BPMC's competition here
VNRX vs CERE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VNRX is priced at $1.28, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CERE's P/E ratio is -16.47. In terms of profitability, VNRX's ROE is +0.74%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VNRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CERE's competition here
VNRX vs APGE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, VNRX is priced at $1.28, while APGE trades at $132.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas APGE's P/E ratio is -30.61. In terms of profitability, VNRX's ROE is +0.74%, compared to APGE's ROE of -0.33%. Regarding short-term risk, VNRX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check APGE's competition here
VNRX vs PCVX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, PCVX has a market cap of 8.2B. Regarding current trading prices, VNRX is priced at $1.28, while PCVX trades at $56.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas PCVX's P/E ratio is -8.22. In terms of profitability, VNRX's ROE is +0.74%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, VNRX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check PCVX's competition here
VNRX vs IMVT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, IMVT has a market cap of 8B. Regarding current trading prices, VNRX is priced at $1.28, while IMVT trades at $38.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas IMVT's P/E ratio is -14.55. In terms of profitability, VNRX's ROE is +0.74%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, VNRX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check IMVT's competition here
VNRX vs PTGX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, PTGX has a market cap of 7.8B. Regarding current trading prices, VNRX is priced at $1.28, while PTGX trades at $121.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas PTGX's P/E ratio is -67.34. In terms of profitability, VNRX's ROE is +0.74%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, VNRX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check PTGX's competition here
VNRX vs RYTM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, VNRX is priced at $1.28, while RYTM trades at $109.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RYTM's P/E ratio is -35.09. In terms of profitability, VNRX's ROE is +0.74%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, VNRX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RYTM's competition here
VNRX vs MTSR Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VNRX is priced at $1.28, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VNRX's ROE is +0.74%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, VNRX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check MTSR's competition here
VNRX vs PTCT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, PTCT has a market cap of 7B. Regarding current trading prices, VNRX is priced at $1.28, while PTCT trades at $84.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas PTCT's P/E ratio is -36.24. In terms of profitability, VNRX's ROE is +0.74%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, VNRX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check PTCT's competition here
VNRX vs LQDA Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, LQDA has a market cap of 6.9B. Regarding current trading prices, VNRX is priced at $1.28, while LQDA trades at $78.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas LQDA's P/E ratio is 557.43. In terms of profitability, VNRX's ROE is +0.74%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, VNRX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check LQDA's competition here
VNRX vs PRAX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, VNRX is priced at $1.28, while PRAX trades at $327.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas PRAX's P/E ratio is -24.52. In terms of profitability, VNRX's ROE is +0.74%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, VNRX is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check PRAX's competition here
VNRX vs MRUS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VNRX is priced at $1.28, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VNRX's ROE is +0.74%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, VNRX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check MRUS's competition here
VNRX vs ACLX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VNRX is priced at $1.28, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VNRX's ROE is +0.74%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VNRX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ACLX's competition here
VNRX vs RETA Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VNRX is priced at $1.28, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RETA's P/E ratio is -66.29. In terms of profitability, VNRX's ROE is +0.74%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VNRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RETA's competition here
VNRX vs SRRK Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, VNRX is priced at $1.28, while SRRK trades at $54.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas SRRK's P/E ratio is -15.25. In terms of profitability, VNRX's ROE is +0.74%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, VNRX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check SRRK's competition here
VNRX vs COGT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, COGT has a market cap of 6.5B. Regarding current trading prices, VNRX is priced at $1.28, while COGT trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas COGT's P/E ratio is -18.06. In terms of profitability, VNRX's ROE is +0.74%, compared to COGT's ROE of -0.83%. Regarding short-term risk, VNRX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check COGT's competition here
VNRX vs ABVX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, VNRX is priced at $1.28, while ABVX trades at $97.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ABVX's P/E ratio is -51.00. In terms of profitability, VNRX's ROE is +0.74%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VNRX is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check ABVX's competition here
VNRX vs CGON Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, VNRX is priced at $1.28, while CGON trades at $71.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CGON's P/E ratio is -30.88. In terms of profitability, VNRX's ROE is +0.74%, compared to CGON's ROE of -0.23%. Regarding short-term risk, VNRX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check CGON's competition here
VNRX vs CNTA Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VNRX is priced at $1.28, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VNRX's ROE is +0.74%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VNRX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CNTA's competition here
VNRX vs MIRM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, VNRX is priced at $1.28, while MIRM trades at $123.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MIRM's P/E ratio is -9.09. In terms of profitability, VNRX's ROE is +0.74%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, VNRX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check MIRM's competition here
VNRX vs LGND Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, VNRX is priced at $1.28, while LGND trades at $303.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas LGND's P/E ratio is 36.40. In terms of profitability, VNRX's ROE is +0.74%, compared to LGND's ROE of +0.16%. Regarding short-term risk, VNRX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check LGND's competition here
VNRX vs BLTE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BLTE has a market cap of 6B. Regarding current trading prices, VNRX is priced at $1.28, while BLTE trades at $148.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BLTE's P/E ratio is -79.53. In terms of profitability, VNRX's ROE is +0.74%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, VNRX is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check BLTE's competition here
VNRX vs CDTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VNRX is priced at $1.28, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VNRX's ROE is +0.74%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, VNRX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CDTX's competition here
VNRX vs ABCM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VNRX is priced at $1.28, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VNRX's ROE is +0.74%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VNRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ABCM's competition here
VNRX vs ISEE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VNRX is priced at $1.28, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VNRX's ROE is +0.74%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VNRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ISEE's competition here
VNRX vs TVTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, VNRX is priced at $1.28, while TVTX trades at $58.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TVTX's P/E ratio is -267.50. In terms of profitability, VNRX's ROE is +0.74%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, VNRX is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check TVTX's competition here
VNRX vs SYRE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, SYRE has a market cap of 5.3B. Regarding current trading prices, VNRX is priced at $1.28, while SYRE trades at $87.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas SYRE's P/E ratio is -42.25. In terms of profitability, VNRX's ROE is +0.74%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, VNRX is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check SYRE's competition here
VNRX vs LEGN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, LEGN has a market cap of 5.3B. Regarding current trading prices, VNRX is priced at $1.28, while LEGN trades at $28.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas LEGN's P/E ratio is -42.19. In terms of profitability, VNRX's ROE is +0.74%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, VNRX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check LEGN's competition here
VNRX vs CRSP Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, VNRX is priced at $1.28, while CRSP trades at $54.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CRSP's P/E ratio is -10.75. In terms of profitability, VNRX's ROE is +0.74%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, VNRX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CRSP's competition here
VNRX vs MANE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, VNRX is priced at $1.28, while MANE trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MANE's P/E ratio is -40.29. In terms of profitability, VNRX's ROE is +0.74%, compared to MANE's ROE of -0.95%. Regarding short-term risk, VNRX is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check MANE's competition here
VNRX vs APLS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VNRX is priced at $1.28, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas APLS's P/E ratio is 38.35. In terms of profitability, VNRX's ROE is +0.74%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VNRX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check APLS's competition here
VNRX vs CAI Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CAI has a market cap of 5.2B. Regarding current trading prices, VNRX is priced at $1.28, while CAI trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CAI's P/E ratio is -101.82. In terms of profitability, VNRX's ROE is +0.74%, compared to CAI's ROE of +0.06%. Regarding short-term risk, VNRX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check CAI's competition here
VNRX vs ERAS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, VNRX is priced at $1.28, while ERAS trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ERAS's P/E ratio is -36.39. In terms of profitability, VNRX's ROE is +0.74%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, VNRX is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check ERAS's competition here
VNRX vs DFTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, VNRX is priced at $1.28, while DFTX trades at $44.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas DFTX's P/E ratio is N/A. In terms of profitability, VNRX's ROE is +0.74%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, VNRX is less volatile compared to DFTX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check DFTX's competition here
VNRX vs CELC Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CELC has a market cap of 4.9B. Regarding current trading prices, VNRX is priced at $1.28, while CELC trades at $99.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CELC's P/E ratio is -25.63. In terms of profitability, VNRX's ROE is +0.74%, compared to CELC's ROE of -2.45%. Regarding short-term risk, VNRX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check CELC's competition here
VNRX vs TERN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VNRX is priced at $1.28, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TERN's P/E ratio is -51.41. In terms of profitability, VNRX's ROE is +0.74%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VNRX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check TERN's competition here
VNRX vs XENE Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, XENE has a market cap of 4.7B. Regarding current trading prices, VNRX is priced at $1.28, while XENE trades at $59.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas XENE's P/E ratio is -12.71. In terms of profitability, VNRX's ROE is +0.74%, compared to XENE's ROE of -0.49%. Regarding short-term risk, VNRX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check XENE's competition here
VNRX vs FOLD Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VNRX is priced at $1.28, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VNRX's ROE is +0.74%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VNRX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check FOLD's competition here
VNRX vs AKRO Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VNRX is priced at $1.28, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VNRX's ROE is +0.74%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, VNRX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check AKRO's competition here
VNRX vs EWTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, VNRX is priced at $1.28, while EWTX trades at $41.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas EWTX's P/E ratio is -24.98. In terms of profitability, VNRX's ROE is +0.74%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, VNRX is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check EWTX's competition here
VNRX vs ALPN Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VNRX is priced at $1.28, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VNRX's ROE is +0.74%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VNRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check ALPN's competition here
VNRX vs VKTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, VKTX has a market cap of 4.4B. Regarding current trading prices, VNRX is priced at $1.28, while VKTX trades at $38.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas VKTX's P/E ratio is -9.19. In terms of profitability, VNRX's ROE is +0.74%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, VNRX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check VKTX's competition here
VNRX vs ACAD Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, VNRX is priced at $1.28, while ACAD trades at $25.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas ACAD's P/E ratio is 12.41. In terms of profitability, VNRX's ROE is +0.74%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, VNRX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check ACAD's competition here
VNRX vs NAMSW Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, VNRX is priced at $1.28, while NAMSW trades at $21.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas NAMSW's P/E ratio is -12.06. In terms of profitability, VNRX's ROE is +0.74%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, VNRX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check NAMSW's competition here
VNRX vs OPT Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VNRX is priced at $1.28, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas OPT's P/E ratio is -1.52. In terms of profitability, VNRX's ROE is +0.74%, compared to OPT's ROE of +1.09%. Regarding short-term risk, VNRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check OPT's competition here
VNRX vs MRTX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VNRX is priced at $1.28, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VNRX's ROE is +0.74%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VNRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check MRTX's competition here
VNRX vs DNLI Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, DNLI has a market cap of 4.1B. Regarding current trading prices, VNRX is priced at $1.28, while DNLI trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas DNLI's P/E ratio is -8.88. In terms of profitability, VNRX's ROE is +0.74%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, VNRX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check DNLI's competition here
VNRX vs DNTH Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, VNRX is priced at $1.28, while DNTH trades at $95.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas DNTH's P/E ratio is -23.10. In terms of profitability, VNRX's ROE is +0.74%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, VNRX is less volatile compared to DNTH. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check DNTH's competition here
VNRX vs TNGX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, VNRX is priced at $1.28, while TNGX trades at $31.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TNGX's P/E ratio is -37.92. In terms of profitability, VNRX's ROE is +0.74%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, VNRX is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check TNGX's competition here
VNRX vs NAMS Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, VNRX is priced at $1.28, while NAMS trades at $33.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas NAMS's P/E ratio is -20.91. In terms of profitability, VNRX's ROE is +0.74%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, VNRX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check NAMS's competition here
VNRX vs CRNX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, VNRX is priced at $1.28, while CRNX trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CRNX's P/E ratio is -7.15. In terms of profitability, VNRX's ROE is +0.74%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VNRX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CRNX's competition here
VNRX vs CPRX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VNRX is priced at $1.28, while CPRX trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CPRX's P/E ratio is 11.33. In terms of profitability, VNRX's ROE is +0.74%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VNRX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CPRX's competition here
VNRX vs RYZB Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VNRX is priced at $1.28, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VNRX's ROE is +0.74%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VNRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check RYZB's competition here
VNRX vs CBAY Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VNRX is priced at $1.28, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VNRX's ROE is +0.74%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VNRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check CBAY's competition here
VNRX vs TLX Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, VNRX is priced at $1.28, while TLX trades at $10.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas TLX's P/E ratio is -580.29. In terms of profitability, VNRX's ROE is +0.74%, compared to TLX's ROE of -0.02%. Regarding short-term risk, VNRX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for VNRX.Check TLX's competition here
VNRX vs BEAM Comparison June 2026
VNRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VNRX stands at 7.6M. In comparison, BEAM has a market cap of 3.6B. Regarding current trading prices, VNRX is priced at $1.28, while BEAM trades at $34.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VNRX currently has a P/E ratio of -0.61, whereas BEAM's P/E ratio is -11.19. In terms of profitability, VNRX's ROE is +0.74%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, VNRX is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for VNRX.Check BEAM's competition here